Breaking News

Jubilant Biosys, Checkpoint in Exclusive Out-Licensing Pact

Checkpoint to develop family of novel BET Inhibitors

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Jubilant Biosys Ltd., a subsidiary of Jubilant Life Sciences Ltd., and Checkpoint Therapeutics, Inc. entered an exclusive, worldwide license agreement under which Jubilant Biosys will out-license to Checkpoint a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment.     Jubilant Biosys will receive $2 million upfront and preclinical, clinical, regulatory, and commercial milestones of as much as $180 million, as ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters